Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc.

TeLuRide-005 Phase 2: ORR 63.1%, DCR 90.8% in 1L stage 4 NSCLC (n=65 evaluable).
Non-squamous cohort: ORR 55.6%, DCR 83.3%, median DOR >11 months at 13.6 months follow-up.
Squamous cohort: ORR 72.4%, DCR 100% with median follow-up 8.8 months (data maturing).
EIK1003 monotherapy (Cohort 1A): ORR 14.3% overall (26.7% PARP-naïve), median DOR 7.8 months in responders.
EIK1003 + paclitaxel (Cohort 1C): ORR 24.5% (29.6% in platinum-resistant ovarian, 19.2% in breast).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.